Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of advanced thyroid cancer: role of molecularly targeted therapies.

Literature DB >> 26335853

Treatment of advanced thyroid cancer: role of molecularly targeted therapies.

Abstract

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.

Entities: Chemical

Mesh：

Substances：

Year: 2015 PMID： 26335853 DOI： 10.1007/s11523-014-0331-z

Source DB: PubMed Journal: Target Oncol ISSN： 1776-2596 Impact factor: 4.493

71 in total

Review 1. Vascular endothelial growth factor in thyroid cancers.

Authors: Jen-Der Lin; Tzu-Chieh Chao
Journal: Cancer Biother Radiopharm Date: 2005-12 Impact factor: 3.099

2. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors: David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958

3. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors: Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal: Lancet Date: 2014-04-24 Impact factor: 79.321

4. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.

Authors: Clarissa Capp; Simone Magagnin Wajner; Débora Rodrigues Siqueira; Beatriz Assis Brasil; Luise Meurer; Ana Luiza Maia
Journal: Thyroid Date: 2010-08 Impact factor: 6.568

5. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Authors: Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; Susan Percy Ivy; Charles Erlichman
Journal: Lancet Oncol Date: 2010-09-17 Impact factor: 41.316

6. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors: P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal: Cancer Res Date: 1997-11-01 Impact factor: 12.701

7. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Authors: Panayiotis Savvides; Govardhanan Nagaiah; Pierre Lavertu; Pingfu Fu; John J Wright; Robert Chapman; Jay Wasman; Afshin Dowlati; Scot C Remick
Journal: Thyroid Date: 2013-04-18 Impact factor: 6.568

8. Phase II trial of sorafenib in metastatic thyroid cancer.

Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544

9. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

Authors: R D Harvey; T K Owonikoko; C M Lewis; A Akintayo; Z Chen; M Tighiouart; S S Ramalingam; M P Fanucchi; P Nadella; A Rogatko; D M Shin; B El-Rayes; F R Khuri; J S Kauh
Journal: Br J Cancer Date: 2013-01-15 Impact factor: 7.640

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

5 in total

1. A Retrospective Study of Serum Calcium Status in Tehran, Iran (105,128 Samples, from 2009-2018).

Authors: Dariush D Farhud; Marjan Zarif-Yeganeh; Atefeh Mehrabi; Ali-Reza Afshari; Mohammad Bagher Rokni; Keyvan Majidi; Maryam Jalali; Ali Akbar Amir Zargar; Abdolfattah Sarafnejad; Hamid Reza Sadeghipour; Shaghayegh Zokaei; Farideh Khosravi; Mahmoud Jalali; Mohammad Khazeni
Journal: Iran J Public Health Date: 2022-04 Impact factor: 1.479